Source: European Medicines Agency (EU) Revision Year: 2026 Publisher: Eli Lilly Nederland B.V., Orteliuslaan 1000, 3528 BD Utrecht, The Netherlands
ABASAGLAR 100 units/mL solution for injection in a cartridge.
| Pharmaceutical Form |
|---|
|
Solution for injection (injection). Clear, colourless solution. |
Each mL contains 100 units insulin glargine* (equivalent to 3.64 mg).
Each cartridge contains 3 mL of solution for injection, equivalent to 300 units.
* produced by recombinant DNA technology in Escherichia coli.
For the full list of excipients, see section 6.1.
| Active Ingredient |
|---|
|
Insulin glargine is a human insulin analogue designed to have a low solubility at neutral pH. After injection, the acidic solution is neutralised leading to formation of a precipitate from which small amounts of insulin glargine are continuously released. |
| List of Excipients |
|---|
|
Zinc oxide |
3 mL solution in a cartridge (type 1 colourless glass) with a plunger (halobutyl rubber) and a disc seal (laminate of polyisoprene and halobutyl rubber) with aluminium seal.
Packs of 5 and 10 cartridges. Not all pack sizes may be marketed.
Eli Lilly Nederland B.V., Orteliuslaan 1000, 3528 BD Utrecht, The Netherlands
EU/1/14/944/003
EU/1/14/944/009
Date of first authorisation: 9 September 2014
Date of latest renewal: 25 July 2019
| Drug | Countries | |
|---|---|---|
| ABASAGLAR | Austria, Cyprus, Estonia, Spain, Finland, France, Croatia, Ireland, Lithuania, Netherlands, Poland, Romania, United Kingdom |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.